Issell B F, Tihon C, Curry M E
Cancer Chemother Pharmacol. 1982;7(2-3):113-5. doi: 10.1007/BF00254531.
In order to determine if any inherent sensitivity differences may exist between VP16-213 and VM26 individual human tumors were grown in vitro and drug sensitivities were determined using the soft agar clonogenic assay method. Only nine of the 34 tumors tested so far showed a differing sensitivity to VP16-213 and VM26 as measured by a 25% or greater colony number reduction. However in none of these tumors did this added reduction result in a 70% decrease over control plate colony numbers. As yet we have been unable to demonstrate any clinically meaningful inherent in vitro sensitivity difference between VP16-213 and VM26 in any tumor type tested.
为了确定VP16 - 213和VM26之间是否可能存在任何内在的敏感性差异，将个体人类肿瘤在体外培养，并使用软琼脂克隆形成试验方法测定药物敏感性。到目前为止测试的34个肿瘤中，只有9个对VP16 - 213和VM26表现出不同的敏感性，通过菌落数减少25%或更多来衡量。然而，在这些肿瘤中，没有一个因这种额外的减少而导致菌落数比对照平板减少70%。迄今为止，我们还无法在任何测试的肿瘤类型中证明VP16 - 213和VM26之间存在任何具有临床意义的内在体外敏感性差异。
